Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 30, 2024, serves as a report of foreign private issuer transactions. The document discloses share trading activities by board members, executives, and associated persons in compliance with Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a disclosure of insider trading activity.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only reported activity is the purchase of American Depositary Receipts (ADRs) by an executive.
Management Commentary and Unusual Items
The filing details a specific transaction by Douglas Langa, Executive Vice President. On August 28, 2024, he purchased a total of 16,789 ADRs on the New York Stock Exchange. The transaction occurred in two tranches at prices of DKK 904.41 and DKK 904.35 per ADR, with an aggregated transaction value of DKK 15,183.93. This is an initial notification of the trade.
Investor Verification Checklist
- Verify the identity of the executive (Douglas Langa) and his current role as Executive Vice President.
- Confirm the transaction date (August 28, 2024) and the exchange (New York Stock Exchange).
- Validate the total volume of ADRs purchased (16,789) and the aggregated price in DKK.
- Note that this filing contains no financial results; refer to the company's Form 20-F or quarterly reports for financial data.